RxDoctor Payments Data

Ruchi Shah

Family · Maitland, FLNPI 1235301409

Payments from drug & device makers

$1,529in general payments, 2019–2025

Across 48 payments — averaging $31.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$897
  • Myriad Genetic Laboratories, Inc.$157
  • Merz North America, Inc.$108
  • Coloplast$75
  • ABC Home Medical Supply, Inc.$69
  • Galderma Laboratories, L.p.$32
  • plus $190 from 9 others

What the payments were for

  • Food & beverage$1,529100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,529 in reported general payments places this provider in the 75th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$24,578
Medicare patients
217
Services billed
629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron45$27,989
Silodosin62$4,021
Finasteride186$2,901
Tamsulosin Hcl232$2,698
Tolterodine Tartrate ErTolterodine Tartrate14$1,769
Oxybutynin Chloride ErOxybutynin Chloride77$1,742
Testosterone20$1,370
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim96$685
Alfuzosin Hcl ErAlfuzosin Hcl27$649
NitrofurantoinNitrofurantoin Macrocrystal37$568
Testosterone Cypionate15$376
Tadalafil12$367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$19$27,98945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 14,618 family providers in Florida.

Other family in Maitland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →